NAUTILUS BIOTECHNOLOGY, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.755 USD | -0.90% |
|
+18.22% | -6.69% |
| 04-30 | Transcript : Nautilus Biotechnology, Inc., Q1 2024 Earnings Call, Apr 30, 2024 | |
| 04-30 | Nautilus Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 643.2 | 224.5 | 373.7 | 348.2 | - | - |
| Enterprise Value (EV) 1 | 297.5 | 40.03 | 200.2 | 266.9 | 325.2 | 213.2 |
| P/E ratio | -8.63 x | -3.91 x | -5.86 x | -3.71 x | -3.33 x | -3.12 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 568 x | 28 x | 8.45 x |
| EV / Revenue | - | - | - | 435 x | 26.1 x | 5.17 x |
| EV / EBITDA | -7.16 x | -0.77 x | -3.22 x | -2.9 x | -3.53 x | -2.33 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | 1.77 x | 0.71 x | 1.41 x | 1.76 x | 2.96 x | 3.97 x |
| Nbr of stocks (in thousands) | 124,167 | 124,724 | 124,969 | 125,265 | - | - |
| Reference price 2 | 5.180 | 1.800 | 2.990 | 2.780 | 2.780 | 2.780 |
| Announcement Date | 24/02/22 | 23/02/23 | 28/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 0.613 | 12.44 | 41.22 |
| EBITDA 1 | - | -41.54 | -52.02 | -62.17 | -91.91 | -92 | -91.63 |
| EBIT 1 | - | -50.5 | -63.62 | -76.15 | -95.16 | -104.4 | -104 |
| Operating Margin | - | - | - | - | -15,524.18% | -839.35% | -252.39% |
| Earnings before Tax (EBT) 1 | - | -50.32 | -57.92 | -63.68 | -96 | -107.6 | -118.4 |
| Net income 1 | -15.62 | -50.32 | -57.92 | -63.68 | -96 | -107.6 | -118.4 |
| Net margin | - | - | - | - | -15,660.69% | -864.65% | -287.26% |
| EPS 2 | - | -0.6000 | -0.4600 | -0.5100 | -0.7500 | -0.8350 | -0.8900 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 26/03/21 | 24/02/22 | 23/02/23 | 28/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | 0.3065 | 1.088 | 2 |
| EBITDA 1 | -14.02 | -13.63 | -12.62 | -12.64 | -13.12 | -14.82 | -15.48 | -15.5 | -16.37 | -17.98 | -18.7 | -20.7 | -23.1 | -21.8 | -21.2 |
| EBIT 1 | -16.82 | -16.02 | -15.47 | -15.82 | -16.3 | -18.06 | -19.02 | -19.08 | -20 | -21.61 | -22.6 | -24.63 | -26.55 | -25.1 | -25.8 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | -8,661.12% | -2,307.86% | -1,290% |
| Earnings before Tax (EBT) 1 | -16.69 | -15.76 | -14.69 | -14.06 | -13.41 | -14.96 | -15.81 | -15.88 | -17.02 | -18.73 | -22.5 | -24.9 | -27 | -27.9 | -27.2 |
| Net income 1 | -16.69 | -15.76 | -14.69 | -14.06 | -13.41 | -14.96 | -15.81 | -15.88 | -17.02 | -18.73 | -22.5 | -24.9 | -27 | -27.9 | -27.2 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | -8,809.14% | -2,565.52% | -1,360% |
| EPS 2 | -0.1300 | -0.1300 | -0.1200 | -0.1100 | -0.1100 | -0.1200 | -0.1300 | -0.1300 | -0.1400 | -0.1500 | -0.1800 | -0.2000 | -0.2100 | -0.2200 | -0.2200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 24/02/22 | 03/05/22 | 02/08/22 | 01/11/22 | 23/02/23 | 02/05/23 | 02/08/23 | 31/10/23 | 28/02/24 | 30/04/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 346 | 184 | 173 | 81.3 | 23.1 | 135 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -30.1% | -17.1% | -21.9% | -36.8% | -64.5% | -63% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 2.920 | 2.520 | 2.120 | 1.580 | 0.9400 | 0.7000 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 26/03/21 | 24/02/22 | 23/02/23 | 28/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.78
USD
Average target price
4.25
USD
Spread / Average Target
+52.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.69% | 348M | |
| +25.21% | 42.68B | |
| -2.56% | 42.4B | |
| +45.32% | 40.04B | |
| -6.20% | 28.31B | |
| +7.80% | 24.94B | |
| -20.09% | 18.96B | |
| +29.48% | 12.3B | |
| -2.66% | 11.95B | |
| -1.53% | 11.55B |
- Stock Market
- Equities
- NAUT Stock
- Financials Nautilus Biotechnology, Inc.
